ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,949.17
-0.60%
US Tech 100
20,289.60
-0.98%
Dow Jones
43,750.86
-0.47%
Brent Oil
72.21
0.00%
Bitcoin
88,302.05
1.09%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Biora Therapeutics Inc (BIOR)

  7. Biora Therapeutics Inc (BIOR) News

Biora Therapeutics Inc

Biora Therapeutics Inc (BIOR)

NASDAQ
2.38
-0.11
(-4.42%)
At close: November 14 4:00PM
Delayed by 15 minutes
2.3606
-0.0194
( -0.82% )
After Hours: 6:11PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

BIOR News

Official News Only

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
August 23 2024
BIOR (-4.42%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
August 23 2024
BIOR (-4.42%)

Form 8-K - Current report
Edgar (US Regulatory)
August 21 2024
BIOR (-4.42%)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Edgar (US Regulatory)
August 20 2024
BIOR (-4.42%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
August 16 2024
BIOR (-4.42%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
August 16 2024
BIOR (-4.42%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
August 12 2024
BIOR (-4.42%)

Form 8-K - Current report
Edgar (US Regulatory)
August 12 2024
BIOR (-4.42%)

Form 8-K - Current report
Edgar (US Regulatory)
August 12 2024
BIOR (-4.42%)

Form 8-K - Current report
Edgar (US Regulatory)
July 18 2024
BIOR (-4.42%)

BIOR Discussion

View Posts
Monksdream Monksdream 1 week ago
BIOR, new 52 week low
👍️0
Monksdream Monksdream 2 weeks ago
BIOR, new 52 week low
👍️0
The Night Stalker The Night Stalker 6 months ago
nice
👍️0
Arnold25764 Arnold25764 7 months ago
Any possible catalyst here?
👍️0
Monksdream Monksdream 7 months ago
BIOR new 52 lo
👍️0
Monksdream Monksdream 7 months ago
BIOR new 52 lo
👍️0
Monksdream Monksdream 8 months ago
BIOR 10Q due 3/26
👍️0
Monksdream Monksdream 8 months ago
BIOR under $2
👍️0
glenn1919 glenn1919 8 months ago
BIOR.................................https://stockcharts.com/h-sc/ui?s=BIOR&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 9 months ago
BIOR..................................https://stockcharts.com/h-sc/ui?s=BIOR&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 11 months ago
BIOR new 52 week low
👍️0
Monksdream Monksdream 11 months ago
BOIR new 52 week low
👍️0
Monksdream Monksdream 11 months ago
BIOR new 52 week low
👍️0
TheFinalCD TheFinalCD 12 months ago
https://finviz.com/quote.ashx?t=BIOR&p=d

https://dilutiontracker.com/app/search/BIOR
👍️0
Awl416 Awl416 12 months ago
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
👍️0
retireat40 retireat40 1 year ago
Looked good this morning at 2.66 but a crappy close.
👍️0
Monksdream Monksdream 1 year ago
BIOR Barchart Bottom 100
Biora Therapeutics Inc NASDAQ: BIOR



GoSymbol lookup
Health Care : Biotechnology | Small Cap ValueCompany profile
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and needle-free delivery of biotherapeutics. The Company's therapeutics pipeline includes two therapeutic delivery platforms: NAVICAP and BIOJET. NAVICAP is a targeted oral delivery platform of therapeutics to the site of disease in the GI tract, designed to improve outcomes for patients with inflammatory bowel disease (IBD). The NAVICAP drug delivery device is an investigational, clinical-stage, single-use ingestible device approximately the size of a fish oil capsule. BIOJET is a systemic oral delivery platform of biotherapeutics designed to replace injection with needle-free, oral delivery of molecules for better management of chronic diseases. The Company's targeted therapeutics pipeline programs include NAVICAP, BT-600 and BT-001. Its systemic therapeutics pipeline programs include BIOJET, BT-200 and BT-002.
👍️0

Your Recent History

NASDAQ
BIOR
Biora Therapeutics
TSXV
GMZ
Minecorp Energy Ltd.
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved